<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=129980757405201&amp;ev=PageView&amp;noscript=1">
  TRC-logo.png
The Role of New Drugs

for Systolic Heart Failure
Systolic_HeartFailure_Slides.png

 

 

Fill out the form to watch the webinar now

This TRC Hot Topic webinar features an expert panel discussion on the pros and cons of Entresto (sacubitril/valsartan) or Corlanor (ivabradine) for the treatment of systolic heart failure, or heart failure with reduced ejection fraction. Listen as heart failure experts give guidance on pressing questions:

  • What is "standard treatment" of heart failure with reduced ejection fraction?
  • When should Entresto be considered instead of an ACEI or ARB?
  • What are the risks associated with starting Entresto?
  • How should patients be switched from an ACEI or ARB to Entresto?
  • What is the role of Corlanor  in heart failure with reduced ejection fraction?